Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 62Rectal Neoplasms 49Breast Neoplasms 48Stomach Neoplasms 37Esophageal Neoplasms 35Colorectal Neoplasms 33Lung Neoplasms 30Squamous Cell Carcinoma of Head and Neck 28Pancreatic Neoplasms 25Brain Neoplasms 25Glioblastoma 23Neoplasms 22Sarcoma 21Neoplasm Metastasis 20Carcinoma, Hepatocellular 18Head and Neck Neoplasms 17Glioma 16Esophageal Squamous Cell Carcinoma 16Colonic Neoplasms 13Recurrence 11Ovarian Neoplasms 10Oropharyngeal Neoplasms 10Melanoma 10Astrocytoma 10Adenocarcinoma Of Esophagus 10Thyroid Neoplasms 9Hypopharyngeal Neoplasms 9Prostatic Neoplasms 8Laryngeal Neoplasms 8Central Nervous System Neoplasms 8

Interventions

pembrolizumab 1infigratinib 1enfortumab vedotin 1Surgical Procedures, Operative 1Specimen Handling 1Nephroureterectomy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Renal Pelvis and Ureter Urothelial Carcinoma × Surgical Procedures, Operative × Clear all
NCT04228042 2025-01-01

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
15 enrolled 10 charts
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡